<![CDATA[Background: Anemia in pregnant women is one of the global health problems experienced by developed or developing countries affecting 1.62 billion world population, which corresponds to 24.8% of the population in the world. Anemia is a serious problem for maternal health because it is one of the five problems that becomes the target of solving the World Health Organization (WHO) in 2025. This study aimed to estimate the magnitude of the effect of Ferric Carboxymaltose on hemoglobin levels in pregnant women with anemia compared to Iron Sucrose.Subjects and Method: This study was a meta-analysis study. The study was conducted by looking for data from the study results in the period 2010-2019. The data of this study was from Pubmed, DOAJ, Science Direct, Springer Link, Web of Science, Cochrane, Google Scholar, BMJ, BMC, Research Gate, J Stor, Wiley, Clinical Key, J Gate, SAGE, IEEE Xplore, ERIC Institute of Education Science, BASE, SciELO, WorldCat, Microsoft Academic, Index Copernicus, CABI, Cambridge, Nature, Oxford, ProQuest, and BJOG using the keyword "ferric carboxymaltose" AND "iron sucrose" AND "anemia in pregnancy" AND "randomized control trial" OR RCT, "ferric carboxymaltose" AND "iron sucrose" AND "hemoglobin in pregnancy" AND "randomized control trial". The subjects of this study were pregnant women with anemia. The study used a Revman 5.3 application to analyze the article.Results: The eight articles were reviewed using the meta-analysis technique in this study. Pregnant women who were given ferric carboxymaltose therapy had a higher mean hemoglobin level than those who were not treated carboxymaltose therapy and it was statistically significant (SMD= 1.11; 95% CI= 0.37 to 1.85; p= 0.003). The heterogeneity of the data showed I2= 98% so that the distribution of the data was stated to be heterogeneous (random effect model).Conclusion: Ferric Carboxymaltose is effective in increasing hemoglobin levels in pregnant women with anemia.Keywords: Ferric Carboxymaltose, Iron Sucrose, Randomized Controlled Trial.Correspondence: Astika Candra Nirwana. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java. Email: astikacandranirwana2796@gmail.com. Mobile: 085640018896.Journal of Maternal and Child Health (2021), 06(01): 15-24https://doi.org/10.26911/thejmch.2021.06.01.02. ]]>
